Clinical Management of Adverse Effects Associated with Domestic Lenvatinib in Hepatocellular Carcinoma Patients under Volume-Based Procurement Policy
Asian Case Reports in Emergency Medicine · 2026 · 14 (02) · 282-288
DOI: 10.12677/acrem.2026.142035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Case Reports in Emergency Medicine, 2026. Verfasst von 凯鑫 靳. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Objective
To systematically review the spectrum of adverse reactions to domestic Lenvatinib in the first-line treatment of unresectable Hepatocellular Carcinoma (HCC), and summarize the hierarchical management strategies.
Methods
55 patients with HCC who received single-agent domestic Lenvatinib from January 2023 to January 2025 were included. Adverse reactions were recorded according to CTCAE 5.0 standards, and a hierarchical intervention and dose adjustment plan was formulated in conjunction with a Multidisciplinary Team (MDT).
Results
52 cases (94.55%) developed adverse reactions, of which 34.55% were grade ≥ 3. The most common event was hypertension (58.18%, grade ≥ 3 21.82%), followed by gastrointestinal reaction (36.36%, grade ≥ 3 5.45%), proteinuria (30.91%, grade ≥ 3 9.09%), transaminases increased (34.55%, grade ≥ 3 5.45%), etc.; no grade 4 or fatal events occurred. After symptomatic treatment, dose reduction or temporary drug discontinuation, all patients were relieved and treatment was resumed.
Conclusions
The types and incidence of adverse reactions of domestically produced Lenvatinib observed in this study cohort are consistent with the data from pivotal clinical trials of the original drug. In this study, through a management model incorporating early monitoring, timely graded intervention, and MDT collaboration, all adverse reactions were effectively controlled, improving patient tolerance and continuous medication rate.
Zitieren
APA
靳, 凯. (2026). Clinical Management of Adverse Effects Associated with Domestic Lenvatinib in Hepatocellular Carcinoma Patients under Volume-Based Procurement Policy. Asian Case Reports in Emergency Medicine, 14(02), 282-288. https://doi.org/10.12677/acrem.2026.142035
Vancouver
靳 凯. Clinical Management of Adverse Effects Associated with Domestic Lenvatinib in Hepatocellular Carcinoma Patients under Volume-Based Procurement Policy. Asian Case Reports in Emergency Medicine. 2026;14(02):282-288. doi:10.12677/acrem.2026.142035
BibTeX
@article{2026,
author = {靳, 凯鑫},
title = {Clinical Management of Adverse Effects Associated with Domestic Lenvatinib in Hepatocellular Carcinoma Patients under Volume-Based Procurement Policy},
journal = {Asian Case Reports in Emergency Medicine},
year = {2026},
volume = {14},
number = {02},
pages = {282--288},
doi = {10.12677/acrem.2026.142035}
}
EUVIMED